294862-75-2

Upstream product

• 26832-08-6 imidazole-4-carboxamide 
• 294862-88-7 1-[2-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]-1H-6-benzyloxyindole 
• 742105-14-2 (S)-4-(6-benzyloxyindol-1-yl)-1-(tert-butyldimethylsilyloxy)butan-2-ol 

Downstream Products

• 294863-03-9 1-[(R)-1-(tert-butyldimethylsilyloxy)-4-[6-(3-(4-chlorophenyl)propoxy)indol-1-yl]-2-butyl]imidazole-4-carboxamide 
• 294863-02-8 1-[(R)-1-(tert-butyldimethylsilyloxy)-4-(6-(4-phenylbutoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide 
• 294863-00-6 1-[(R)-1-(tert-butyldimethylsilyloxy)-4-(6-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide 

Relevant academic research and scientific papers

Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors

We disclose herein optimization efforts around the novel, highly potent non-nucleoside adenosine deaminase (ADA) inhibitor, 1-[(R)-1-hydroxy-4-(6-(3-(1- methylbenzimidazol-2-yl)propionylamino)indol-1-yl)-2-butyl]imidazole-4- carboxamide 1 (Ki =

Heterocyclic compound, composition and method for inhibiting adenosine deaminase

Heterocyclic compounds of the following formula: wherein B is ?[wherein R1is hydrogen or lower alkyl; R2is hydrogen or lower alkyl; and X is hydrogen or hydroxy protective group], lower alkanoyl or hydroxyimino(lower)alkyl A is lower